Lipocine Inc LPCN 深 沪
等待开盘 04-03 09:30:00 美东时间
2.05
-7.200
-77.84%
华盛通- 最 高2.11
- 今 开2.01
- 成交量 698.61万股
- 最 低 1.81
- 昨 收 9.25
- 总市值 1496.44万
- 52周最高 12.37
- 市盈率 静 --
- 换手率 95.70%
- 52周最低 1.81
- 委 比 84.00%
- 总股本 729.97万
- 历史最高 340.00
- 量 比 64.01
- 振 幅 3.24%
- 历史最低 1.81
- 每 手 1
- 风险率 2.48%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Lipocine's LPCN 1154 Misses Phase 3 Primary Endpoint in Postpartum Depression; Shows Early Efficacy Signals In Patients With Prior Psychiatric History And Maintains Favorable Safety Profile
In the Phase 3 study population (N=90) of patients with PPD, LPCN 1154 did not show a statistically significant reduction from baseline in HAM-D17 total score compared to placebo at hour 60 (primary endpoint); the
04-02 20:13
Lipocine FY 2025 revenue fell 82% to USD 1.98 million as net loss was USD 9.63 million
Lipocine FY 2025 revenue fell 82% to USD 1.98 million as net loss was USD 9.63 million Lipocine reported a FY 2025 net loss of USD 9.6 million, or USD 1.69 per diluted share, compared with net income of USD 8,352 a year earlier. FY 2025 revenue fell 82% to USD 2 million, mainly reflecting lower lice
03-10 18:13
Lipocine FY2025 revenue fell 82% to USD 1.98 million as net loss totaled USD 9.6 million
Lipocine FY2025 revenue fell 82% to USD 1.98 million as net loss totaled USD 9.6 million Lipocine reported a FY 2025 net loss of USD 9.6 million, compared with net income of USD 8,000 a year earlier. FY 2025 revenue fell 82% to USD 1.98 million, driven mainly by USD 1.5 million of license revenue an
03-10 18:03
Lipocine Reports Last Patient Last Visit in Phase 3 Trial of LPCN 1154 for Postpartum Depression
Lipocine Reports Last Patient Last Visit in Phase 3 Trial of LPCN 1154 for Postpartum Depression Lipocine Inc. reported that the last patient completed the final study visit (last patient last visit) in its pivotal Phase 3 randomized, double-blind, placebo-controlled trial of LPCN 1154 (oral brexano
02-18 21:08
美股大行评级 | 奈飞绩后遭13家大行下调目标价；齐昂银行、美国合众银行获多家机构上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从9美元升至50美元；韦德布什：维持Ardelyx, Inc."跑赢大市"评级，目标价从16美元升至19美元
01-22 15:09
U.S. RESEARCH ROUNDUP-IBM, KLA, WEX
U.S. RESEARCH ROUNDUP-IBM, KLA, WEX Jan 21 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including IBM, KLA and WEX, on Wednesday. HIGHLIGHTS * IBM IBM.N : JP Morgan raises target price to $312 from $290 * KLA Corp KLAC.O : Deut
01-21 16:26
Lipocine Completes Enrollment, Patient Dosing In Its Phase 3 Clinical Study Of LPCN 1154 To Treat Postpartum Depression
Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective oral delivery, today announced that enrollment and participant dosing
01-20 21:10
Lipocine Nears Full Enrollment In Phase 3 PPD Trial, Topline Results Expected Q2 2026
Second Drug Safety Monitoring Board (DSMB) meeting update planned for mid-January 2026Topline results on track for the second quarter of 2026SALT LAKE CITY, Dec. 16, 2025 /PRNewswire/ -- Lipocine Inc. (NASDAQ:LPCN), a
2025-12-16 21:10
Lipocine Showcases LPCN 2101 at Epilepsy Meeting
An update from Lipocine ( ($LPCN) ) is now available. Lipocine presented poster...
2025-12-12 06:28
